[Therapeutic angiogenesis as a new experimental treatment for vascular disease].
Currently, our treatment modalities for patients with severe coronary artery disease consist of combinations of medication, percutaneous transluminal coronary angioplasty (PTCA) and coronary revascularization operations. Still, the number of patients who cannot be treated adequately in these ways is growing. In recent years progress has been made in the field of angiogenesis: the process of the development of new capillaries. It is now known that blood vessel growth is an essential phenomenon in a range of disease. It is possible to inhibit or stimulate this process, offering hope for new treatments in a wide array of diseases. Stimulation of angiogenesis has already been successful in animal models of chronic peripheral and myocardial ischaemia. Results of experimental treatments of coronary patients have been reported since 1998. 'Therapeutic angiogenesis' may evolve as our fourth treatment modality for the treatment of coronary artery insufficiency.
Lucassen
A M
AM
Hartcentrum, Academisch Ziekenhuis St. Radboud, Nijmegen. a.lucassen@cardio.azn.nl
de Waal
R M
RM
Verheugt
F W
FW
D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000818:Animals; D002196:Capillaries / Q000187:drug effects / Q000254:growth & development; D003327:Coronary Disease / Q000188:drug therapy / Q000628:therapy*; D016228:Endothelial Growth Factors / Q000494:pharmacology* / Q000627:therapeutic use; D016222:Fibroblast Growth Factor 2 / Q000627:therapeutic use*; D006801:Humans; D008222:Lymphokines / Q000627:therapeutic use; D018919:Neovascularization, Physiologic / Q000187:drug effects* / Q000502:physiology; D020033:Protein Isoforms / Q000627:therapeutic use; D014652:Vascular Diseases / Q000628:therapy; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D020533:Angiogenesis Inhibitors; D016228:Endothelial Growth Factors; D008222:Lymphokines; D020033:Protein Isoforms; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D016222:Fibroblast Growth Factor 2